Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

By D. Sargent, S. Marsoni, G. Monges, S. Thibodeau, R. Labianca, S. Hamilton, A. French, B. Kabat, N. Foster, V. Torri and 7 more. Journal of Clinical Oncology, 2010

1,552 citations recorded by the source corpus.

Subfields: Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/106ec35038853fbc0be05727f652461f0fda30b0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pathology and Forensic Medicine

Citations in the corpus

Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. (2020, background): “In particular, MSI/MMR may be useful to identify a small (10%–15%) subset of stage II patients who are at a very low risk of recurrence and in whom the benefits of fluoropyrimidines have not been demonstrated and thus adjuvant chemotherapy should not be indicated [I, A] [51-55].”
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer (2016, background): “S tus in the tumor defines a low-risk group in which adjuvant chemotherapy is not beneficial (6, 7).”
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. (2012, background): “• Pooled analyses have suggested a detrimental effect for adjuvant treatment with 5-fluorouracil (5-FU) in patients with stage II MSI-H/dMMR tumours, what could not be confirmed by recent analyses from randomized trials (PETACC 3, QUASAR) [18, 31–33].”
Impact of BRAF Mutation and Microsatellite Instability on the Pattern of Metastatic Spread and Prognosis in Metastatic Colorectal Cancer (2011, background): “Tumors with low-level MSI or microsatellite stable (MSS) tumors are grouped together and referred to as MSS, as extensive data indicate the 2 molecular phenotypes are biologically similar.(16) Recorded metastatic sites are representative of metastases that have developed over the course of the patie”
A clinically applicable molecular-based classification for endometrial cancers (2015, background): “Finally, identification of MMR IHC abn tumours may prove to have predictive implications in EC, as observed in colorectal cancers (Bertagnolli et al, 2009; Sargent et al, 2010; Sinicrope et al, 2011), that would influence choice of treatment.”